The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

lorcainid     N-(4-chlorophenyl)-2-phenyl- N-(1-propan-2...

Synonyms: LORCAINIDE, Lorcainida, Lorcainidum, CHEMBL87543, SureCN364045, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Lorcainide hydrochloride

 

High impact information on Lorcainide hydrochloride

 

Chemical compound and disease context of Lorcainide hydrochloride

 

Biological context of Lorcainide hydrochloride

 

Anatomical context of Lorcainide hydrochloride

  • Abnormal sinus node function may be exacerbated by lorcainide treatment, however, and bundle branch block may be precipitated in patients with pre-existing conduction system disease [18].
  • Intravenous and oral lorcainide: assessment of central nervous system toxicity and antiarrhythmic efficacy [19].
  • H-V intervals, pooled H-V intervals and QRS-width lengthened in all patients, most markedly in cases with a conduction delay below the His bundle, who had received lorcainide 2.5 mg/kg [20].
  • Only minor amounts (less than 1% of the dose) of unchanged lorcainide could be recovered in urine and feces and total plasma clearance averaged 121.5 ml/min/kg [21].
  • Within 2 h the decline of these concentrations was very rapid and after 8 h lorcainide could be detected only in spleen, lung and adipose tissue [21].
 

Associations of Lorcainide hydrochloride with other chemical compounds

 

Gene context of Lorcainide hydrochloride

 

Analytical, diagnostic and therapeutic context of Lorcainide hydrochloride

References

  1. Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia. Echt, D.S., Mitchell, L.B., Kates, R.E., Winkle, R.A. Circulation (1983) [Pubmed]
  2. Lorcainide in patients with refractory ventricular tachyarrhythmia. Chesnie, B., Lampert, S., Podrid, P., Lown, B. J. Am. Coll. Cardiol. (1984) [Pubmed]
  3. Comparison of intravenous lorcainide with lidocaine for acute therapy of complex ventricular arrhythmias: results of a randomized study with crossover option. Anderson, J.L., Anastasiou-Nana, M., Lutz, J.R., Writer, S.L. J. Am. Coll. Cardiol. (1985) [Pubmed]
  4. Congestive heart failure induced by six of the newer antiarrhythmic drugs. Ravid, S., Podrid, P.J., Lampert, S., Lown, B. J. Am. Coll. Cardiol. (1989) [Pubmed]
  5. The clinical pharmacology of lidocaine congeners--review of encainide, flecainide, lorcainide and tocainide. McDevitt, D.G. Eur. Heart J. (1984) [Pubmed]
  6. Cardiac electrophysiology of four new antiarrhythmic drugs--encainide, flecainide, lorcainide and tocainide. Camm, A.J. Eur. Heart J. (1984) [Pubmed]
  7. Lorcainide disposition kinetics in arrhythmia patients. Kates, R.E., Keefe, D.L., Winkle, R.A. Clin. Pharmacol. Ther. (1983) [Pubmed]
  8. Electrophysiological effects of lorcainide in sinoatrial disease and in Wolff-Parkinson-White syndrome. Manz, M., Steinbeck, G., Lüderitz, B. Eur. Heart J. (1982) [Pubmed]
  9. Chronic lorcainide therapy for symptomatic premature ventricular complexes: efficacy, pharmacokinetics and evidence for norlorcainide antiarrhythmic effect. Mead, R.H., Keefe, D.L., Kates, R.E., Winkle, R.A. Am. J. Cardiol. (1985) [Pubmed]
  10. Comparison of lorcainide and quinidine in the treatment of ventricular ectopy. Vlay, S.C., Mallis, G.I., Singh, S., Cohn, P.F. Chest (1984) [Pubmed]
  11. Evaluation of lorcainide in patients with symptomatic ventricular tachycardia. Somberg, J.C., Butler, B., Flowers, D., Keefe, D., Torres, V., Miura, D. Am. J. Cardiol. (1984) [Pubmed]
  12. Effect of SUN 1165, a new potent antiarrhythmic agent, on the kinetics of rate-dependent block of Na channels and ventricular conduction of extrasystoles. Hattori, Y., Hidaka, T., Aisaka, K., Satoh, F., Ishihara, T. J. Cardiovasc. Pharmacol. (1988) [Pubmed]
  13. Clinical pharmacokinetics of the newer antiarrhythmic agents. Gillis, A.M., Kates, R.E. Clinical pharmacokinetics. (1984) [Pubmed]
  14. Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent. Klotz, U., Müller-Seydlitz, P., Heimburg, P. Clinical pharmacokinetics. (1978) [Pubmed]
  15. Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide. Campbell, T.J., Vaughan Williams, E.M. Cardiovasc. Res. (1983) [Pubmed]
  16. Pharmacokinetic implications of lorcainide therapy in patients with normal and depressed cardiac function. Somani, P., Fraker, T.D., Temesy-Armos, P.N. Journal of clinical pharmacology. (1987) [Pubmed]
  17. Drug interaction between lorcainide and rifampicin. Mauro, V.F., Somani, P., Temesy-Armos, P.N. Eur. J. Clin. Pharmacol. (1987) [Pubmed]
  18. Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Eiriksson, C., Brogden, R.N. Drugs (1984) [Pubmed]
  19. Intravenous and oral lorcainide: assessment of central nervous system toxicity and antiarrhythmic efficacy. Vlay, S.C., Mallis, G.I. Am. Heart J. (1986) [Pubmed]
  20. Intracardiac electrophysiological effects of lorcainide in man. Ng, C.K., Gstöttner, M., Gmeiner, R. Eur. J. Clin. Pharmacol. (1979) [Pubmed]
  21. The pharmacokinetics and tissue distribution of the new antiarrhythmic agent lorcainide (R 15889) in rats. Klotz, U., Golbs, E. Arzneimittel-Forschung. (1980) [Pubmed]
  22. Rate-dependent depression of maximal rate of depolarization in guinea pig papillary muscle action potentials by changrolin. Kuang, Y., Liu, T.P. Zhongguo yao li xue bao = Acta pharmacologica Sinica. (1990) [Pubmed]
  23. Electrophysiological effects of a new antiarrhythmic agent, lorcainide, on the isolated cardiac muscle fiber as compared with disopyramide. Shigenobu, K., Atoda, H., Asano, T., Kasuya, Y. J. Pharmacobio-dyn. (1980) [Pubmed]
  24. Comparative effects of procainamide, tocainide and lorcainide on Na(+)-K(+)-ATPase in guinea pig heart preparations. Dzimiri, N., Almotrefi, A.A. Gen. Pharmacol. (1991) [Pubmed]
  25. Effect of lorcainide, a new antiarrhythmic compound, on the changes in heart rhythm induced by intravenous injection of adenosine-5'-diphosphate in rats. De Clerck, F., Van Gorp, L., Xhonneux, R. Archives internationales de pharmacodynamie et de thérapie. (1978) [Pubmed]
  26. Lorcainide (R 15 889), a first review. Amery, W.K., Heykants, J.J., Xhonneux, R., Towse, G., Oettel, P., Gough, D.A., Janssen, P.A. Acta cardiologica. (1981) [Pubmed]
  27. Comparison of the antiarrhythmic activity of mexiletine and lorcainide on ventricular arrhythmias. Meinertz, T., Kasper, W., Stengel, E., Waldecker, B., Löllgen, H., Jähnchen, E., Bechtold, H., Just, J. Zeitschrift für Kardiologie. (1982) [Pubmed]
  28. Long-term lorcainide therapy in patients with ventricular tachycardia. Somberg, J., Butler, B., Flowers, D., Keefe, D., Torres, V., Miura, D. Am. Heart J. (1985) [Pubmed]
  29. Lorcainide for high-frequency ventricular arrhythmia: preliminary results of a short-term double-blind and placebo-controlled crossover study and long-term follow-up. Singh, S.N., DiBianco, R., Kostroff, L.I., Fletcher, R.D., Cockrell, J.L. Am. J. Cardiol. (1984) [Pubmed]
  30. Lorcainide for the treatment of refractory ventricular tachycardia: clinical and electrophysiologic results. Hanyok, J.J., Kluger, J., Chow, M.S., Fieldman, A. Journal of clinical pharmacology. (1987) [Pubmed]
 
WikiGenes - Universities